ArticleDiscover oncology2026
Survival outcomes in TTF-1 negative non-squamous non-small cell lung cancer (H-LINK 001).
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe impact of TTF-1 expression on outcomes in patients with non-squamous non-small cell lung cancer (NSCLC) has increasingly been reported. However, information on the characteristics and outcomes of patients with non-squamous NSCLC in whom TTF-1-negativity was confirmed using different antibody clones remains scarce.
methodsWe conducted a multicenter retrospective study and analyzed the data of patients with non-squamous NSCLC in which TTF-1-negativity was confirmed in each participating institution. Patients were eligible if they had an EGFR/ALK-wild type tumor and received first-line treatment with an immune checkpoint-containing regimen. Clinical information, including the TTF-1-antibody used in each institution, was collected.
resultsData of 70 patients with non-squamous NSCLC and negative TTF-1 expression were analyzed. The patients were subdivided into SPT24- and 8G7G3/1-confirmed groups according to the TTF-1-antibody clone used to confirm TTF-1-negativity. Multivariate analysis using the Cox proportional hazard model revealed that the SPT24-confirmed group had a significantly increased risk of death (hazard ratio: 3.20, 95% confidence interval: 1.23 − 8.29), but not a significant association with the risk of disease progression. Meanwhile, the neutrophil/lymphocyte ratio was significantly associated with both the risk of disease progression and death.
conclusionTTF-1-negative non-squamous NSCLC patients who were diagnosed using the SPT24 antibody clone exhibited significantly shorter overall survival than those who were diagnosed using the 8G7G3/1 antibody clone, and NLR may be a useful predictor for the prognosis of patients with TTF-1-negative non-squamous cell NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.